{"id":70080,"date":"2026-07-16T16:02:15","date_gmt":"2026-07-16T08:02:15","guid":{"rendered":"https:\/\/flcube.com\/?p=70080"},"modified":"2026-07-16T16:02:16","modified_gmt":"2026-07-16T08:02:16","slug":"lepu-medical-secures-nmpa-clinical-trial-approval-for-mwn110-novel-actriia-b-antibody-for-weight-management","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=70080","title":{"rendered":"Lepu Medical Secures NMPA Clinical Trial Approval for MWN110, Novel ActRIIA\/B Antibody for Weight Management"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Lepu Medical Technology<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/300003:SHE\">SHE: 300003<\/a>) announced on July 15, 2026, that the <strong>National Medical Products Administration (NMPA)<\/strong> has approved its investigational drug <strong>MWN110<\/strong> for clinical trials targeting <strong>weight management in adults<\/strong>. The drug represents a novel approach to obesity treatment with potential advantages over traditional GLP-1 receptor agonists.<\/p>\n\n\n\n<h2 id=\"h-regulatory-milestone-key-details\" class=\"wp-block-heading\">Regulatory Milestone | Key Details<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Component<\/th><th>Specification<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>Lepu Medical Technology (SHE: 300003)<\/td><\/tr><tr><td><strong>Drug Candidate<\/strong><\/td><td>MWN110<\/td><\/tr><tr><td><strong>Regulatory Authority<\/strong><\/td><td>NMPA (China)<\/td><\/tr><tr><td><strong>Approval Type<\/strong><\/td><td>Clinical trial approval<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Weight management in adults<\/td><\/tr><tr><td><strong>Announcement Date<\/strong><\/td><td>July 15, 2026<\/td><\/tr><tr><td><strong>Development Stage<\/strong><\/td><td>Preclinical to Phase I transition<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-drug-profile-amp-mechanism-of-action\" class=\"wp-block-heading\">Drug Profile &amp; Mechanism of Action<\/h2>\n\n\n\n<h3 id=\"h-molecular-characteristics\" class=\"wp-block-heading\">Molecular Characteristics<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Class:<\/strong> ActRIIA\/B-targeting monoclonal antibody<\/li>\n\n\n\n<li><strong>Origin:<\/strong> Independently developed by <strong>Shanghai Minwei Biotechnology<\/strong><\/li>\n\n\n\n<li><strong>Intellectual Property:<\/strong> Global rights held by Shanghai Minwei Biotechnology<\/li>\n\n\n\n<li><strong>Target:<\/strong> Activin receptor type IIA\/B (ActRIIA\/B) pathway<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-differentiated-therapeutic-benefits\" class=\"wp-block-heading\">Differentiated Therapeutic Benefits<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">MWN110 is expected to deliver distinct clinical advantages compared to traditional GLP-1 receptor agonists:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Fat reduction<\/strong> without significant muscle loss<\/li>\n\n\n\n<li><strong>Muscle mass preservation<\/strong> during weight loss<\/li>\n\n\n\n<li><strong>Reduced weight rebound<\/strong> post-treatment<\/li>\n\n\n\n<li>Potential for improved <strong>body composition outcomes<\/strong><\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-strategic-partnership-framework\" class=\"wp-block-heading\">Strategic Partnership Framework<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">While Lepu Medical announced the NMPA approval, the drug was <strong>independently developed by Shanghai Minwei Biotechnology<\/strong>, which retains <strong>global intellectual property rights<\/strong>. This suggests a strategic collaboration or licensing arrangement between the two companies, leveraging Lepu Medical&#8217;s regulatory expertise and commercial infrastructure in China while Shanghai Minwei maintains global development rights.<\/p>\n\n\n\n<h2 id=\"h-market-context-amp-competitive-landscape\" class=\"wp-block-heading\">Market Context &amp; Competitive Landscape<\/h2>\n\n\n\n<h3 id=\"h-obesity-treatment-market-dynamics\" class=\"wp-block-heading\">Obesity Treatment Market Dynamics<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>GLP-1 receptor agonists<\/strong> currently dominate the weight management market with drugs like semaglutide and tirzepatide<\/li>\n\n\n\n<li><strong>Market size:<\/strong> Estimated at <strong>$100+ billion globally<\/strong> by 2030<\/li>\n\n\n\n<li><strong>Key limitations<\/strong> of current therapies: muscle mass loss, weight rebound after discontinuation, gastrointestinal side effects<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-mwn110-s-competitive-positioning\" class=\"wp-block-heading\">MWN110&#8217;s Competitive Positioning<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">By targeting the <strong>ActRIIA\/B pathway<\/strong>, MWN110 addresses a different biological mechanism than GLP-1 agonists:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Myostatin inhibition<\/strong> promotes muscle preservation<\/li>\n\n\n\n<li><strong>Activin signaling modulation<\/strong> supports fat metabolism<\/li>\n\n\n\n<li>Potential for <strong>combination therapy<\/strong> with GLP-1 agonists to optimize body composition outcomes<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">This approach aligns with emerging scientific understanding that optimal weight management should focus not just on total weight loss, but on <strong>improving body composition<\/strong> through fat reduction while preserving lean muscle mass.<\/p>\n\n\n\n<h2 id=\"h-development-outlook\" class=\"wp-block-heading\">Development Outlook<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">The NMPA clinical trial approval enables Lepu Medical to initiate human studies in China, potentially accelerating development timelines compared to Western regulatory pathways. Given the massive obesity burden in China\u2014estimated at <strong>over 500 million adults<\/strong> with overweight or obesity\u2014the domestic market alone represents significant commercial opportunity.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Success in early clinical trials could position MWN110 as a <strong>differentiated second-generation obesity therapeutic<\/strong> with unique body composition benefits that address key limitations of current standard-of-care treatments.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward-Looking Statements<\/strong><br>This brief contains forward-looking statements regarding clinical development, regulatory approvals, and market opportunities. Actual results may differ due to risks including clinical trial outcomes, regulatory decisions, and competitive dynamics.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/\u4e50\u666e\u533b\u7597\uff1a\u5173\u4e8e\u5b50\u516c\u53f8MWN110\u6ce8\u5c04\u6db2\u83b7\u5f97\u836f\u7269\u4e34\u5e8a\u8bd5\u9a8c\u6279\u51c6\u901a\u77e5\u4e66\u7684\u516c\u544a.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of \u4e50\u666e\u533b\u7597\uff1a\u5173\u4e8e\u5b50\u516c\u53f8MWN110\u6ce8\u5c04\u6db2\u83b7\u5f97\u836f\u7269\u4e34\u5e8a\u8bd5\u9a8c\u6279\u51c6\u901a\u77e5\u4e66\u7684\u516c\u544a.\"><\/object><a id=\"wp-block-file--media-f36a7dcd-ca04-4cb1-883a-2ccbe5866220\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/\u4e50\u666e\u533b\u7597\uff1a\u5173\u4e8e\u5b50\u516c\u53f8MWN110\u6ce8\u5c04\u6db2\u83b7\u5f97\u836f\u7269\u4e34\u5e8a\u8bd5\u9a8c\u6279\u51c6\u901a\u77e5\u4e66\u7684\u516c\u544a.pdf\">\u4e50\u666e\u533b\u7597\uff1a\u5173\u4e8e\u5b50\u516c\u53f8MWN110\u6ce8\u5c04\u6db2\u83b7\u5f97\u836f\u7269\u4e34\u5e8a\u8bd5\u9a8c\u6279\u51c6\u901a\u77e5\u4e66\u7684\u516c\u544a<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/\u4e50\u666e\u533b\u7597\uff1a\u5173\u4e8e\u5b50\u516c\u53f8MWN110\u6ce8\u5c04\u6db2\u83b7\u5f97\u836f\u7269\u4e34\u5e8a\u8bd5\u9a8c\u6279\u51c6\u901a\u77e5\u4e66\u7684\u516c\u544a.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-f36a7dcd-ca04-4cb1-883a-2ccbe5866220\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Lepu Medical Technology (SHE: 300003) announced on July 15, 2026, that the National Medical Products&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,11],"tags":[62,374,86,864],"class_list":["post-70080","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-clinical-trial-approval-initiation","tag-lepu-medical-technology","tag-obesity","tag-she-300003"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.0) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Lepu Medical Secures NMPA Clinical Trial Approval for MWN110, Novel ActRIIA\/B Antibody for Weight Management - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Lepu Medical Technology (SHE: 300003) announced on July 15, 2026, that the National Medical Products Administration (NMPA) has approved its investigational drug MWN110 for clinical trials targeting weight management in adults. The drug represents a novel approach to obesity treatment with potential advantages over traditional GLP-1 receptor agonists.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=70080\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Lepu Medical Secures NMPA Clinical Trial Approval for MWN110, Novel ActRIIA\/B Antibody for Weight Management\" \/>\n<meta property=\"og:description\" content=\"Lepu Medical Technology (SHE: 300003) announced on July 15, 2026, that the National Medical Products Administration (NMPA) has approved its investigational drug MWN110 for clinical trials targeting weight management in adults. The drug represents a novel approach to obesity treatment with potential advantages over traditional GLP-1 receptor agonists.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=70080\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-07-16T08:02:15+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-07-16T08:02:16+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70080#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70080\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Lepu Medical Secures NMPA Clinical Trial Approval for MWN110, Novel ActRIIA\\\/B Antibody for Weight Management\",\"datePublished\":\"2026-07-16T08:02:15+00:00\",\"dateModified\":\"2026-07-16T08:02:16+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70080\"},\"wordCount\":464,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Clinical trial approval \\\/ initiation\",\"Lepu Medical Technology\",\"Obesity\",\"SHE: 300003\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=70080#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70080\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=70080\",\"name\":\"Lepu Medical Secures NMPA Clinical Trial Approval for MWN110, Novel ActRIIA\\\/B Antibody for Weight Management - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-07-16T08:02:15+00:00\",\"dateModified\":\"2026-07-16T08:02:16+00:00\",\"description\":\"Lepu Medical Technology (SHE: 300003) announced on July 15, 2026, that the National Medical Products Administration (NMPA) has approved its investigational drug MWN110 for clinical trials targeting weight management in adults. The drug represents a novel approach to obesity treatment with potential advantages over traditional GLP-1 receptor agonists.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70080#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=70080\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70080#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Lepu Medical Secures NMPA Clinical Trial Approval for MWN110, Novel ActRIIA\\\/B Antibody for Weight Management\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Lepu Medical Secures NMPA Clinical Trial Approval for MWN110, Novel ActRIIA\/B Antibody for Weight Management - Insight, China&#039;s Pharmaceutical Industry","description":"Lepu Medical Technology (SHE: 300003) announced on July 15, 2026, that the National Medical Products Administration (NMPA) has approved its investigational drug MWN110 for clinical trials targeting weight management in adults. The drug represents a novel approach to obesity treatment with potential advantages over traditional GLP-1 receptor agonists.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=70080","og_locale":"en_US","og_type":"article","og_title":"Lepu Medical Secures NMPA Clinical Trial Approval for MWN110, Novel ActRIIA\/B Antibody for Weight Management","og_description":"Lepu Medical Technology (SHE: 300003) announced on July 15, 2026, that the National Medical Products Administration (NMPA) has approved its investigational drug MWN110 for clinical trials targeting weight management in adults. The drug represents a novel approach to obesity treatment with potential advantages over traditional GLP-1 receptor agonists.","og_url":"https:\/\/flcube.com\/?p=70080","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-07-16T08:02:15+00:00","article_modified_time":"2026-07-16T08:02:16+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=70080#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=70080"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Lepu Medical Secures NMPA Clinical Trial Approval for MWN110, Novel ActRIIA\/B Antibody for Weight Management","datePublished":"2026-07-16T08:02:15+00:00","dateModified":"2026-07-16T08:02:16+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=70080"},"wordCount":464,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Clinical trial approval \/ initiation","Lepu Medical Technology","Obesity","SHE: 300003"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=70080#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=70080","url":"https:\/\/flcube.com\/?p=70080","name":"Lepu Medical Secures NMPA Clinical Trial Approval for MWN110, Novel ActRIIA\/B Antibody for Weight Management - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-07-16T08:02:15+00:00","dateModified":"2026-07-16T08:02:16+00:00","description":"Lepu Medical Technology (SHE: 300003) announced on July 15, 2026, that the National Medical Products Administration (NMPA) has approved its investigational drug MWN110 for clinical trials targeting weight management in adults. The drug represents a novel approach to obesity treatment with potential advantages over traditional GLP-1 receptor agonists.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=70080#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=70080"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=70080#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Lepu Medical Secures NMPA Clinical Trial Approval for MWN110, Novel ActRIIA\/B Antibody for Weight Management"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/70080","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=70080"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/70080\/revisions"}],"predecessor-version":[{"id":70083,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/70080\/revisions\/70083"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=70080"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=70080"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=70080"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}